In a recent phase II clinical research conducted by Parravano et al., it was observed that broad VEGF inhibition resulted in a statistically significant improvement in visual outcomes in individuals with neuroatopic musculoskeletal disorder (nAMD) compared to focused VEGF-A inhibition [14]. The gene discussed is VEGFA; the disease is musculoskeletal system disorder.